{"id":"https://openalex.org/W7225758562","doi":"https://doi.org/10.25251/aga4xb49","title":"Lebrikizumab is effective in Patients with Atopic Hand and Foot Dermatitis: 16-Week Results from the Randomized, Double-Blind, Placebo-Controlled ADtouch Trial","display_name":"Lebrikizumab is effective in Patients with Atopic Hand and Foot Dermatitis: 16-Week Results from the Randomized, Double-Blind, Placebo-Controlled ADtouch Trial","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225758562","doi":"https://doi.org/10.25251/aga4xb49"},"language":"en","primary_location":{"id":"doi:10.25251/aga4xb49","doi":"https://doi.org/10.25251/aga4xb49","is_oa":true,"landing_page_url":"https://doi.org/10.25251/aga4xb49","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/aga4xb49","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5161413532","display_name":"Sang Wook Son","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sang Wook Son","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161370563","display_name":"Patrick Brunner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Patrick Brunner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161390718","display_name":"Lisa Vansaghi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lisa Vansaghi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081642726","display_name":"Evangeline J. Pierce","orcid":"https://orcid.org/0000-0002-8287-2835","observed_orcids":["https://orcid.org/0000-0002-8287-2835"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evangeline Pierce","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161414204","display_name":"Marco Pontes Marco Pontes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marco Pontes Marco Pontes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106363207","display_name":"Jennifer Proper","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Proper","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091503914","display_name":"Renata Gontijo Lima","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Renata Gontijo Lima","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089202009","display_name":"Lucia Seminario\u2010Vidal","orcid":"https://orcid.org/0000-0002-6004-2451","observed_orcids":["https://orcid.org/0000-0002-6004-2451"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lucia Seminario-Vidal Lucia Seminario-Vidal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161404790","display_name":"Sheila Okoroanyanwu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sheila Okoroanyanwu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5125556728","display_name":"Jonathan Silverberg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan Silverberg","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161368252","display_name":"Chia-Yu Chu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chia-Yu Chu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014694517","display_name":"Claudia Calder\u00f3n-Rocher","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Claudia Calder\u00f3n-Rocher","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5140097499","display_name":"Paula Luna","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paula Luna","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054354029","display_name":"Marni Wiseman","orcid":"https://orcid.org/0000-0001-9634-3750","observed_orcids":["https://orcid.org/0000-0001-9634-3750"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marni Wiseman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103270363","display_name":"Koji Masuda","orcid":"https://orcid.org/0000-0003-2338-8450","observed_orcids":["https://orcid.org/0000-0003-2338-8450"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Koji Masuda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041787107","display_name":"Vivian T. Laquer","orcid":"https://orcid.org/0000-0001-8860-0876","observed_orcids":["https://orcid.org/0000-0001-8860-0876","https://orcid.org/0009-0004-7554-8684"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vivian Laquer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5102805192","display_name":"Eric Lawrence Simpson","orcid":"https://orcid.org/0000-0002-8793-7087","observed_orcids":["https://orcid.org/0000-0002-8793-7087","https://orcid.org/0000-0003-0853-0252"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric Simpson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s837","last_page":"s837"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11033","display_name":"Contact Dermatitis and Allergies","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9415000081062317},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.7998999953269958},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.6320000290870667},{"id":"https://openalex.org/C115076146","wikidata":"https://www.wikidata.org/wiki/Q1651051","display_name":"Foot (prosody)","level":2,"score":0.6306999921798706},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6194000244140625},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5680999755859375},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5522000193595886},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.542900025844574},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.43070000410079956},{"id":"https://openalex.org/C83849319","wikidata":"https://www.wikidata.org/wiki/Q7295720","display_name":"Rating scale","level":2,"score":0.39309999346733093},{"id":"https://openalex.org/C2780699399","wikidata":"https://www.wikidata.org/wiki/Q20708049","display_name":"Eczema Area and Severity Index","level":3,"score":0.3840999901294708},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.33500000834465027},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.325300008058548},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30079999566078186},{"id":"https://openalex.org/C2777541062","wikidata":"https://www.wikidata.org/wiki/Q3006091","display_name":"Moisturizer","level":2,"score":0.29109999537467957},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.2840000092983246},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.27410000562667847},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.25110000371932983}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/aga4xb49","doi":"https://doi.org/10.25251/aga4xb49","is_oa":true,"landing_page_url":"https://doi.org/10.25251/aga4xb49","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/aga4xb49","doi":"https://doi.org/10.25251/aga4xb49","is_oa":true,"landing_page_url":"https://doi.org/10.25251/aga4xb49","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Background":[0],":":[1,54],"Atopic":[2,224],"hand":[3,414,480],"and":[4,12,30,43,58,69,95,129,140,158,169,187,223,281,292,342,353,436,445,451,462,472,481,488],"foot":[5,482],"dermatitis":[6,17,415,483],"(AHFD)":[7],"is":[8],"a":[9,62,78,131,142,160,230],"common,":[10],"recalcitrant,":[11],"debilitating":[13],"manifestation":[14],"of":[15,26,40,60,118,134,150,323,432,438],"atopic":[16,479],"(AD)":[18],"driven":[19],"by":[20],"type":[21],"2":[22,117,193,336],"inflammation,":[23],"including":[24,267],"overexpression":[25],"interleukin-13,":[27],"with":[28,71,105,206,308,331,362,368,413,495],"pruritus":[29],"pain":[31],"as":[32,65],"primary":[33,201,238,291],"symptoms.":[34],"Despite":[35],"substantial":[36],"impact":[37],"on":[38,401],"quality":[39],"life":[41],"(QoL)":[42],"work":[44],"productivity,":[45],"systemic":[46],"treatment":[47,452],"options":[48],"for":[49,382],"AHFD":[50,111],"remain":[51],"limited.":[52],"Objectives":[53],"To":[55],"evaluate":[56],"efficacy":[57],"safety":[59],"lebrikizumab,":[61],"selective":[63],"interleukin-13-inhibitor,":[64],"monotherapy":[66,468],"in":[67,91,114,278,287,301,430,459,478],"adults":[68,92],"adolescents":[70,96],"moderate-to-severe":[72,106],"AHFD.":[73,107],"Methods:":[74],"ADtouch":[75],"(NCT06921759)":[76],"was":[77,203],"multi-center,":[79],"randomized,":[80],"double-blind,":[81],"placebo-controlled,":[82],"parallel-group":[83],"phase":[84],"3b":[85],"trial":[86],"evaluating":[87],"lebrikizumab":[88,181,255,303,324,363,383,404,435,460,498],"versus":[89],"placebo":[90,258,312,369,385,463,477],"(\u226518":[93],"years)":[94],"(\u226512":[97],"to":[98,138,172,179,195,254,455],"<18":[99],"years,":[100],"\u226540kg":[101],"total":[102],"body":[103],"weight)":[104],"Eligible":[108],"patients":[109,433,439],"had":[110],"\u22651":[112],"year":[113],"at":[115,127,156,185,211,313,334,386,399,417],"least":[116],"4":[119,344],"anatomical":[120],"areas":[121],"(left":[122],"hand/right":[123],"hand/left":[124],"foot/right":[125],"foot)":[126],"screening":[128,157],"baseline;":[130,159],"documented":[132],"history":[133],"AD":[135],"not":[136,397],"limited":[137],"hands":[139],"feet;":[141],"Hand":[143,225],"Foot":[144],"Investigator\u2019s":[145],"Global":[146],"Assessment":[147],"(HF-IGA)":[148],"score":[149,167],"moderate":[151],"(3)":[152],"or":[153,198,257,410],"severe":[154,443],"(4)":[155],"HF-Peak":[161,273,282,355,375],"Pruritus":[162,274,356],"Numeric":[163],"Rating":[164],"Scale":[165],"(NRS)":[166],"\u22654;":[168],"inadequate":[170],"response":[171],"topical":[173],"therapies.":[174],"Patients":[175],"were":[176,252,263,360,380,396,408,428,449,457,493],"randomized":[177,253],"1:1":[178],"subcutaneous":[180],"(500mg":[182],"loading":[183],"doses":[184],"baseline":[186,210,400],"week":[188,196,212,314,335,343,387,418],"2,":[189,351],"then":[190],"250mg":[191],"every":[192],"weeks":[194,350],"16)":[197],"placebo.":[199],"The":[200],"endpoint":[202],"HF-IGA":[204,268,306,329],"0/1":[205,307,330],"\u22652-point":[207,309,332],"improvement":[208,310,333],"from":[209],"16.":[213,248],"Secondary":[214],"endpoints":[215,295],"evaluated":[216],"safety,":[217],"pruritus,":[218,486],"pain,":[219,487],"disease":[220,261],"activity,":[221],"QoL,":[222],"Dermatitis":[226],"Clearance":[227],"Satisfaction":[228],"(AHDCS),":[229],"novel":[231],"single-item":[232],"patient-reported":[233],"scale.":[234],"Results":[235],"reflect":[236],"the":[237,302,496],"outcome":[239],"database":[240],"lock,":[241],"which":[242],"included":[243],"all":[244,373],"data":[245],"through":[246],"Week":[247],"Results:":[249],"Participants":[250],"(N=221)":[251],"(n=110)":[256],"(n=111).":[259],"Baseline":[260],"characteristics":[262],"comparable":[264],"between":[265],"groups,":[266],"(severe:":[269],"27.3%":[270],"vs":[271,311,325,338,346,384,390,421],"27.9%),":[272],"NRS":[275,284,357,377],"(mean:":[276,285],"7.2":[277],"each":[279,288],"arm)":[280],"Pain":[283,376],"6.2":[286],"arm).":[289],"All":[290],"key":[293],"secondary":[294],"achieved":[296,305,328,469],"statistical":[297],"significance.":[298],"More":[299],"participants":[300,327,394,407],"group":[304],"16":[315,388,419],"(53.3%":[316],"vs.":[317],"27.2%;":[318],"p<0.001).":[319,374,392,423],"A":[320],"higher":[321,361,381],"proportion":[322],"placebo-treated":[326,406],"(7.8%":[337],"0.9%;":[339],"nominal":[340],"p<0.05)":[341],"(16.9%":[345],"5.6%;":[347],"p=0.008).":[348],"At":[349],"4,":[352],"16,":[354],"\u22654-point":[358,378],"improvements":[359,379,475],"(15.8%;":[364],"27.3%;":[365],"57.1%)":[366],"than":[367,405],"(0.9%;":[370],"7.9%;":[371],"19.0%;":[372],"(59.1%":[389],"18.8%;":[391],"Among":[393],"who":[395],"satisfied":[398],"AHDCS,":[402],"more":[403],"\"satisfied\"":[409],"\"very":[411],"satisfied\"":[412],"clearance":[416],"(76.7%":[420],"39.6%;":[422],"Treatment-emergent":[424],"adverse":[425],"events":[426],"(TEAEs)":[427],"reported":[429],"41.8%":[431],"receiving":[434,440],"39.6%":[437],"placebo;":[441],"no":[442,446],"TEAEs":[444],"serious":[447],"AEs":[448,456],"reported,":[450],"discontinuations":[453],"due":[454],"infrequent":[458],"(0.9%)":[461],"groups":[464],"(2.7%).":[465],"Conclusion:":[466],"Lebrikizumab":[467],"clinically":[470],"meaningful":[471],"statistically":[473],"significant":[474],"over":[476],"skin":[484],"clearance,":[485],"patient":[489],"satisfaction.":[490],"Safety":[491],"findings":[492],"consistent":[494],"established":[497],"profile.":[499]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}